Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and thioflavin T binding

mAbs

Volumn 3, Issue 4, 2011, Pages

  Kayser, Veysel ^a   Chennamsetty, Naresh ^a,b   Voynov, Vladimir ^a,c   Helk, Bernhard ^d   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c MEDIMMUNE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Accelerated studies; Conformational change; Protein aggregation; Stability and shelf life prediction; Therapeutic monoclonal antibody

Indexed keywords

8 ANILINO 1 NAPHTHALENESULFONIC ACID; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; THIOFLAVINE; FLUORESCENT DYE; THIAZOLE DERIVATIVE;

ARTICLE; CONFORMATIONAL TRANSITION; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; PROTEIN AGGREGATION; PROTEIN STABILITY; CHEMISTRY; DRUG STABILITY; GEL CHROMATOGRAPHY; HUMAN; METABOLISM; PROTEIN CONFORMATION; PROTEIN FOLDING; SPECTROFLUOROMETRY; TEMPERATURE;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, GEL; DRUG STABILITY; FLUORESCENT DYES; HUMANS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY; SPECTROMETRY, FLUORESCENCE; TEMPERATURE; THIAZOLES;

EID: 79960108942     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.4.15677     Document Type: Article

References (27)

1. Qu Z, Griffiths GL, Wegener WA, Chang CH, Govindan SV, Horak ID, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005; 36:84; PMID: 15848077; DOI: 10.1016/j.ymeth.2005.01.008.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; DOI: 10.1038/nri1837.
3. Hale G. Therapeutic antibodies - Delivering the promise? Adv Drug Deliv Rev 2006; 58:633; PMID: 16822575; DOI: 10.1016/j.addr.2006.03.010.
4. Mather JP. Engineered antibody therapeutics. Adv Drug Deliv Rev 2006; 58:631; PMID: 16857292; DOI: 10.1016/j.addr.2006.05.001.
5. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability and formulation. J Pharm Sci 2007; 96:1-26; PMID: 16998873; DOI: 10.1002/jps.20727.
6. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006; 58:686-706; PMID: 16839640; DOI: 10.1016/j.addr.2006.03.011.
7. Kayser V, Chennamsetty N, Voynov V, Helk B, Forrer K, Trout BL. Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharm Sci 2011; In press; PMID: 21268027; DOI: 10.1002/jps.22493.
8. Bee JS, Davis M, Freund E, Carpenter JF, Randolph TW. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng 2009; 105:121-9; PMID: 19725039; DOI: 10.1002/bit.22525.
9. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 2010; 99:2200-8; PMID: 19918982; DOI: 10.1002/jps.21989.
10. Stryer L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin: A fluorescent probe of non-polar binding sites. J Mol Biol 1965; 13:482-95; PMID: 5867031; DOI: 10.1016/S0022-2836(6aev 5)80111-5.
11. Semisotnov GV, Rodionova NA, Razguly OI, Uversky VN, Gripas' AF, Gilmanshin RI. Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 1991; 31:119-28; PMID: 2025683; DOI: 10.1002/bip.360310111.
12. Levine HI. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993; 2:404-10; PMID: 8453378; DOI: 10.1002/pro.5560020312.
13. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 2010; 99:1707-20; PMID: 19780136; DOI: 10.1002/jps.21955.
14. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. Characterization of protein aggregation: The case of a therapeutic immunoglobulin. Biochim Biophys Acta 2007; 1774:146-53; PMID: 17142116; DOI: 10.1016/j.bbapap.2006.10.010.
15. Hawe A, Friess W, Sutter M, Jiskoot W. Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem 2008; 378:115-22; PMID: 18455994; DOI: 10.1016/j.ab.2008.03.050.
16. He F, Phan DH, Hogan S, Bailey R, Becker GW, Narhi LO, et al. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci 2010; 99:2598-608; PMID: 20039384; DOI: 10.1002/jps.22036.
17. Demeule B, Palais C, Machaidze G, Gurny R, Arvinte T. New methods allowing the detection of protein aggregates: A case study on trastuzumab. mAbs 2009; 1:142-50; DOI: 10.4161/mabs.1.2.7632.
18. Daniel E, Weber G. Cooperative effects in binding by bovine serum albumin. I. The binding of 1-Anilino-8-naphthalenesulfonate. Fluorimetric titrations. Biochemistry 1966; 5:1893-900; DOI: 10.1021/bi00870a016.
19. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci 1998; 95:4224-8; PMID: 9539718.
20. Van Nuland NAJ, Meijberg W, Warner J, Forge V, Scheek RM, Robillard GT, et al. Slow cooperative folding of a small globular protein HPr. Biochemistry 1998; 37:622-37; PMID: 9425085; DOI: 10.1021/bi9717946.
21. Chang Ls, Wen Ey, Hung Jj, Chang Cc. Energy transfer from tryptophan residues of proteins to 8-anilinonaphthalene-1-sulfonate. Protein J 1994; 13:635-40; PMID: 7702745; DOI: 10.1007/BF01890462.
22. Pedersen S, Nesgaard L, Baptista RP, Melo EP, Kristensen SR, Otzen DE. pH-dependent aggregation of cutinase is efficiently suppressed by 1,8-ANS. Biopolymers 2006; 83:619-29; PMID: 16964599; DOI: 10.1002/bip.20598.
23. Biancalana M, Makabe K, Koide A, Koide S. Molecular mechanism of Thioflavin-T binding to the surface of β-rich peptide self-assemblies. J Mol Biol 2009; 385:1052-63; PMID: 19038267; DOI: 10.1016/j.jmb.2008.11.006.
24. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, et al. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 2005; 151:229-38; PMID: 16125973; DOI: 10.1016/j.jsb.2005.06.006.
25. LeVine H, Ronald W. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309:274-84; PMID: 10507030; DOI: 10.1016/S0076-6879(99)09020-5.
26. Roberts CJ. Kinetics of irreversible protein aggregation: Analysis of extended Lumry-Eyring models and implications for predicting protein shelf life. J Phys Chem B 2003; 107:1194-207; DOI: 10.1021/jp026827s.
27. Murphy RM, Tsai AM. Misbehaving proteins: protein (mis)folding, aggregation and stability. New York Springer Science + Business Media, LLC 2006.